Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

BMJ Case Reports

Volumn , Issue , 2009, Pages

  Paul, F ^a   Dorr J ^b   Wurfel J ^a   Vogel, H P ^b   Zipp, F ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Helios Klinikum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881155330     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.06.2009.2004     Document Type: Article

References (18)

1. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979; 63: 827-34. [Medline] [Web of Science] (Pubitemid 9248185)
2. Cohen BA, Mikol DD. Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 2004; 63: S28-32. [Abstract/FREE Full text] (Pubitemid 40019276)
3. Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Nov antrone) therapy in patients with MS. Neurology 2002; 59: 909-13. [Abstract/FREE Full text]
4. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-63. [CrossRef] [Medline] [Web of Science]
5. Leite-Moreira AF. Current perspectives in diastolic dysfunction and diastolic heart failure. Heart 2006; 92: 712-18. [FREE Full text]
6. Klein AL, Cohen GI. Doppler echocardiographic assessment of constrictive pericarditis, cardiac amyloidosis, and cardiac tamponade. Cleve Clin J Med 1992; 59: 278-90. [Abstract/FREE Full text]
7. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112-18. [Abstract/FREE Full text] (Pubitemid 27090928)
8. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-25. [CrossRef] [Medline] [Web of Science] (Pubitemid 36026580)
9. Kuecherer HF, Kee LL, Modin G, et al. Echocardiography in serial evaluation of left ventricular systolic and diastolic function: importance of image acquisition, quantitation, and physiologic variability in clinical and inv estigational applications. J Am Soc Echocardiogr 1991; 4: 203-14. [Medline]
10. Bellenger NG, Burgess MI, Ray SG, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance imaging; are they interchangeable? Eur Heart J 2000; 21: 1387-96. [Abstract/FREE Full text] (Pubitemid 30599134)
11. McGowan JH, Cleland JG. Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods. Am Heart J 2003; 146: 388-97. [CrossRef] [Medline] [Web of Science] (Pubitemid 37083072)
12. Avasarala JR, Cross AH, Clifford DB, et al. Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 2003; 9: 59-62. [Abstract/FREE Full text] (Pubitemid 36253698)
13. Gonsette RE. Mitoxantrone in progressive multiple sclerosis: when and how to treat? J Neurol Sci 2003; 206: 203-8. [CrossRef ] [Medline] [Web of Science] (Pubitemid 36143729)
14. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989; 118: 92-8. [CrossRef] [Medline] [Web of Science] (Pubitemid 19183582)
15. Stoddard MF, Seeger J, Liddell NE, et al. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992; 20: 62-9. [Medline] [Web of Science]
16. Tjeerdsma G, Meinardi MT, van Der Graaf WTA, et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 1999; 81: 419-23. [Abstract/FREE Full text] (Pubitemid 29167133)
17. Zingler VC, Nabauer M, Jahn K, et al. Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. Eur Neurol 2005; 54: 28-33. [CrossRef] [Medline] [Web of Science] (Pubitemid 41328731)
18. Mortensen SA, Olsen HS, Baandrup U. Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br Heart J 1986; 55: 274-82 [Abstract/FREE Full text] (Pubitemid 16137871)